Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 11/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TXN | P10599 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12233230 | 0.82 | TXN (0.39) | FPR2CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL14752978 | 0.82 | TXN (0.39) | FPR2CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL12207170 | 0.79 | TXN (0.37) | FPR2CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL12234738 | 0.79 | TXN (0.37) | FPR2CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL7277265 | 0.79 | CYP1A2 (0.38) | FPR2CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL9085766 | 0.77 | ALDH1A1 (0.41) | FPR2CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL9638815 | 0.77 | F2RL1 (0.33) | FPR2CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL6285851 | 0.74 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL3602253 | 0.72 | TXN (0.43) | FPR2CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL13066227 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018213821-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY (US) | 2018-11-22 | — | — | WO | claimed |
| US-20240175141-A1 | BIOBASED AND BIODEGRADABLE CORROSION INHIBITION COMPOSITION | ZestBio, Inc. | 2024-05-30 | — | — | US | disclosed |
| WO-2024081967-A2 | BIOBASED AND BIODEGRADABLE CORROSION INHIBITION COMPOSITION | ZestBio, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-3455212-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | Heptares Therapeutics Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| WO-2018213821-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2017194716-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| CN-103193828-B | Double-imidazole imide nickel hydroxide coordination complex as well as preparation method and application thereof | UNIV NORTHWESTERN | 2015-04-15 | — | — | CN | disclosed |
| CN-102659682-B | Imidazole side chain half-metallocene imine ligand, and method and application thereof | UNIV NORTHWESTERN | 2014-07-09 | — | — | CN | disclosed |
| CN-103193828-A | Double-imidazole imide nickel hydroxide coordination complex as well as preparation method and application thereof | UNIV NORTHWESTERN | 2013-07-10 | — | — | CN | disclosed |
| CN-102659682-A | Imidazole side chain half-metallocene imine ligand, and method and application thereof | UNIV NORTHWESTERN | 2012-09-12 | — | — | CN | disclosed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1200457-A2 | CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009169-A2 | CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2001-02-08 | — | — | WO | disclosed |
| EP-0708776-A1 | ANTIALLERGIC IMIDAZOAZEPINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002600-A1 | ANTIALLERGIC IMIDAZOAZEPINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-01-26 | — | — | WO | disclosed |
| EP-0592490-A4 | AMINO ACID DERIVATIVE ANTICONVULSANT | RES CORP TECHNOLOGIES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0592490-A1 | AMINO ACID DERIVATIVE ANTICONVULSANT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | FPR2 4496/4885CYP1A2 38/4885CYP3A4 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.